Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Treatment of Drug Resistant Hypertension
2008-007149-30Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jan 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of spironolactone, doxazosin and bisoprolol in resistant hypertension (RH), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Jan 2009; status: completed.
02
Drugs
spironolactonedoxazosinbisoprolol
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on 2008-007149-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007149-30.